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OBJECTIVE—-Cell proliferation is an important mechanism
underlying -cell mass adaptation to metabolic demands. We
have examined effects, in particular those mediated through
intracellular cAMP signaling, of the incretin hormone analog
exendin-4 on cell cycle regulation in -cells.
RESEARCH DESIGN AND METHODS—Changes in islet pro-
tein levels of cyclins and of two critical cell cycle regulators
cyclin kinase inhibitor p27 and S-phase kinase–associated pro-
tein 2 (Skp2) were assessed in mice treated with exendin-4 and in
a mouse model with speciﬁc upregulation of nuclear cAMP
signaling exhibiting increased -cell proliferation (CBP-S436A
mouse). Because cyclin A2 was stimulated by cAMP, we assessed
the role of cylcin A2 in cell cycle progression in Min6 and isolated
islet -cells.
RESULTS—Mice treated with exendin-4 showed increased
-cell proliferation, elevated islet protein levels of cyclin A2 with
unchanged D-type cyclins, elevated PDX-1 and Skp2 levels, and
reduced p27 levels. Exendin-4 stimulated cyclin A2 promoter
activity via the cAMP–cAMP response element binding protein
pathway. CBP-S436A islets exhibited elevated cyclin A2, reduced
p27, and no changes in D-type cyclins, PDX-1, or Skp2. In
cultured islets, exendin-4 increased cyclin A2 and Skp2 and
reduced p27. Cyclin A2 overexpression in primary islets in-
creased proliferation and reduced p27. In Min6 cells, cyclin A2
knockdown prevented exendin-4–stimulated proliferation.
PDX-1 knockdown reduced exendin-4–stimulated cAMP synthe-
sis and cyclin A2 transcription.
CONCLUSIONS—Cyclin A2 is required for -cell proliferation,
exendin-4 stimulates cyclin A2 expression via the cAMP path-
way, and exendin-4 stimulation of cAMP requires PDX-1.
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P
ancreatic -cell mass is dynamic and responds to
variations in metabolic demand on insulin pro-
duction. The inability of the endocrine pancreas
to adapt to changing insulin demand (inadequate
-cell mass) is found both in type 1 and type 2 diabetes.
Increasing -cell mass by regeneration may ameliorate or
correct both type 1 and 2 diabetes (1). Within the pan-
creas, -cells regenerate predominantly by -cell replica-
tion (2,3). In this context, insight into the mechanisms
underlying -cell proliferation and cell cycle regulation,
may provide potential targets for therapy in situations of
inadequate -cell mass.
The incretin hormone glucagon-like peptide-1 (GLP-1)
and its long-acting peptide analog exendin-4 stimulate
-cell proliferation in vitro and in vivo (4), leading to
increased -cell mass in rodents and amelioration of
glucose metabolism in diabetic animal models and human
diabetic subjects (4). Downstream effectors of the GLP-1
signaling to the cell nucleus include 1) the epidermal
growth factor receptor–phosphoinositol 3-kinase (PI 3-ki-
nase)–protein kinase B (PKB/Akt)–forkhead box tran-
scription factor O1 (FoxO1) pathway (5) and 2) the
cAMP–protein kinase A (PKA)–cAMP response element
binding protein (CREB) pathway (4). Activation of the PI
3-kinase pathway results in phosphorylation and nuclear
exclusion of FoxO1, thereby derepressing PDX-1 tran-
scription (rev. in 6). Insulin and insulin-like growth factor
stimulation of -cell proliferation converge on the PKB/
Akt-FoxO1-PDX-1 pathway (6,7). Transgenic -cell–spe-
ciﬁc overexpression of phosphorylation-defective, nuclear
FoxO1 results in reduced nuclear PDX-1, reduced -cell
number and islet size, and diminished -cell proliferation
response to exendin-4 (5,6). In addition, -cell–speciﬁc
deletion of PDX-1 in adult mice results in reduced re-
sponse to GLP-1 effects on -cell insulin secretion and
proliferation (8), indicating that incretin hormone effects
on -cell proliferation require adequate PDX-1 levels. In
contrast to the PI 3-kinase–mediated pathway, little is
known on the speciﬁc effects of exendin-4 on cell cycle
regulation in -cells via the cAMP-CREB–signaling path-
way (9).
We have interrogated exendin-4 and cAMP-CREB–medi-
ated effects on cell cycle regulation in -cells, taking
advantage of the restricted expression of exendin-4 recep-
tors, which—apart from some areas in the central nervous
system—are found predominantly on pancreatic -cells
(4). In addition, we have used a mouse model with speciﬁc
nuclear upregulation of cAMP-CREB–CREB binding pro-
tein (CBP) action and enhanced in vivo and in vitro -cell
proliferation (9) to speciﬁcally assess the role of cAMP-
CREB–regulated transcription on cell cycle regulation. For
exendin-4 effects on the cell cycle regulatory proteins, we
have focused on cyclins (3,10) and S-phase kinase–associ-
ated protein 2 (Skp2) and p27 (11), which are critical
regulators of cell cycle control in -cells. In contrast to
current understanding that only D-type cyclins respond to
extracellular growth factors, we were surprised to ﬁnd
that in -cells, cyclin A2 expression is upregulated by
exendin-4 directly by cAMP-PKA-CREB-CBP signaling.
Our in vivo studies indicate that upon exendin-4 stimula-
tion of -cells, cyclin A2 protein levels increase, whereas
D-type cyclin levels do not change. In addition, exendin-4
treatment is accompanied by decreased p27 and concom-
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DIABETES, VOL. 57, SEPTEMBER 2008 2371itant increase in Skp2 protein, which in cultured Min6 cells
is stimulated by a PI 3-kinase–dependent pathway. Up-
regulation of cyclin A2 levels by lentiviral infection of
primary murine -cells is sufﬁcient to increase prolifera-
tion activity. Furthermore, our studies suggest that in
-cells, homeodomain transcription factor PDX-1 expres-
sion is necessary for generating cAMP, which is required
for exendin-4 effects on cyclin A2 expression via PKA-
CREB-CBP.
RESEARCH DESIGN AND METHODS
Animal studies were approved in advance by the institutional animal care and
use committee of Johns Hopkins University. All animal studies were con-
ducted with mice 2–3 months of age. C57Bl/6J were treated with exendin-4
in 10 nmol  kg
1  day
1 i.p. PBS for 5 days or PBS only before islet isolation
or tissue extraction. For -cell apoptosis induction, 6-h–fasted mice were
treated with 250 mg/kg streptozotocin (STZ; Sigma-Aldrich) in citrate buffer
(pH 3) i.p. 24 h before pancreas harvest.
CBP-S436A knockin mice, which exhibit enhanced in vivo and in vitro
-cell proliferation (9,12), were back-crossed into C57Bl/6 background for six
generations. CBP phosphorylation at serine 436 interferes with and reduces
CREB/CBP interaction and reduces target gene transcription. Mutation of
serine 436 to alanine (forming the mutant CBP-S436A) leads to enhanced basal
and cAMP-stimulated transcription of CREB-responsive genes not suppressed
by cellular events, which would result in CBP S436 phosphorylation (9,12).
Homozygote and heterozygote CBP-S436A mice have similar islet morphom-
etry (Supplemental Table 1, available in an online appendix at http://dx.
doi.org/10.2337/db07-1541) (11,13) because of the dominant activating CBP-
S436A mutation. Therefore, most studies herein were conducted on
heterozygous (/) knockin mice and wild-type littermates.
Immunoﬂuorescence histology and islet morphometry. Pancreata were
ﬁxed and stained, and islet morphometry was performed as previously
described (9) and as summarized in the supplemental methods available in the
online appendix.
Islet studies. Islets were isolated as previously described (9) and initially
incubated in 24-well culture plates in RPMI-1640, 5 mmol/l glucose supple-
mented with 10% FCS, and 1% penicillin/streptomycin for 24 h before
performing additional procedures. For -cell apoptosis induction, islets were
exposed to 1.5 mmol/l STZ for an additional 24 h before harvest (positive
control of apoptosis). Islet exposure to 20 nmol/l exendin-4 was for 8 h after
the initial time course studies, when islets were exposed for 0, 2, 4, 6, 8, and
12 h to PBS or exendin-4. cDNA synthesis from islet RNA and quantitative
RT-PCR were performed using iScript One-tube RT-PCR with SYBR green on
an iCycler (BioRad). Transcript levels were normalized to expression of
housekeeping gene 36B4 in corresponding samples. PCR protocols and
primers used for quantitative RT-PCR can be obtained on request. For
lentiviral infection, freshly isolated islets were incubated in a microcentrifuge
tube containing concentrated lentivirus (see supplemental methods), centri-
fuged at 2,000 rpm for 2 min, transferred to the a 96-well microtiter plate, and
incubated at 37°C in 95% humidity and 5% CO2. Western immunoblots were
performed with 20–40 g islets protein in radioimmunoprecipitation assay
buffer using standard protocols. Information on antibodies used for immuno-
blots will be provided on request. Immunoblots for cyclin D subtypes were
also performed using monoclonal antibodies (Neomarkers) that are speciﬁc
for cyclin D1–D3 subtypes. Cyclin A1 was not examined because of its
restricted expression to gonads (14). Parallel protein detection for actin was
used to control for protein loading. Band intensity of interrogated protein was
normalized to the corresponding actin intensity (BioRad Chemidoc XRS).
Representative immunoblots are shown. Immunoblots were repeated at least
four times.
Cells and transfections. Min6 cells (passages 25–34) were cultured as
described previously (13). Plasmids used are summarized in the supplemental
methods.
Chromatin-immunoprecipitation assay. Chromatin-immunoprecipitation
(ChIP) assay was performed according to manufacturer’s instructions (ChIP
assay kit; Upstate) to detect binding of CREB and recruitment of CBP to the
CRE containing regulatory elements in the murine insulin (positive control)
and cyclin A2, D1, and D2 genes. ChIP was performed on DNA extracted from
cultured MIN6 treated with or without exendin-4 as described above. Speciﬁc
rabbit anti-CREB antibody (D. Ginty, Johns Hopkins University) or normal
rabbit IgG antibody (Santa Cruz sc-2027) were used for immunoprecipitation.
PCR was performed for 30 cycles of 30 s each of 94°C melting, 58°C annealing,
and 72°C extension steps. An aliquot of the PCR product was fractionated on
a 2% agarose gel containing ethidium bromide for UV visualization.
Small interfering RNA knockdown studies. Small interfering RNA (siRNA)
(100 nmol/l for murine cyclin A2, 200 nmol/l for murine PDX-1, or correspond-
ing amounts for scrambled siRNA; Ambion) were transfected using Fugene
(Roche; 1 or 2.5 l per well in a 24- or 6-well plate, respectively) according to
the manufacturer’s instructions. For siRNA-mediated knockdown in cultured
primary islets, respective siRNA (400 nmol/l with Fugene 10 l per well in
24-well culture plate) was added to the culture medium. Culture medium and
siRNA were replaced every 12 h four times before islet harvest and further
analysis. Primers for cyclin A2 (sense, 5-GCUCAAGACUCGACGGGUtt-3)
and PDX-1 (sense, 5-GGGAACUUAACCUAGGCGUtt-3) effectively reduced
cyclin A2 or PDX-1 (see below) levels as determined by immunoblot and were
used in all subsequent studies, respectively.
cAMP measurements. cAMP measurements were performed on cultured
Min6 and cultured islet extracts. Studies were performed in sextuplicate
(Min6) or quadruplicate (cultured islets), and cAMP was measured by ELISA
according to manufacturer’s instructions (Assay Design).
Statistical analysis. Results are shown as averages and means  SE. Calcu-
lations were conducted using either Prism 4 (Graph Pad) or Excel (Microsoft)
software. Where appropriate, Student’s t test or ANOVA was used to calculate
differences between groups. A P value of 0.05 was considered signiﬁcant and
is indicated with an asterisk.
RESULTS
Exendin-4 treatment increases islet cyclin A2 and
Skp2 protein levels. Of the islet cell population, 75–90%
are -cells. Furthermore, GLP-1 receptor is expressed
primarily on -cells within the pancreatic islet (4), and all
-cells participate equally in proliferation (2,3). Thus,
changes in whole-islet protein extracts reﬂect mainly, if
not exclusively, changes in -cell protein levels (15).
Islet size increased by 1.7-fold in exendin-4–treated
C57Bl/6 mice, consistent with previous observations (16).
This increase is due to -cell hyperplasia and not hyper-
trophy because -cell size did not change (Fig. 1A–F).
Surprisingly, the D-type cyclin levels, which are consid-
ered to respond to extracellular growth stimuli, were not
changed in exendin-4–treated islets. Exendin-4 treatment
was associated with elevated PDX-1 (1.93  0.20, P  0.05)
(as expected; 16), cyclin A2 (2.69  0.17 vs. control, P 
0.05) and Skp2 (5.01  0.98-fold vs. control, P  0.05)
protein levels (Fig. 2A and Table 1). Islet levels of p27 in the
relatively young animals (8–12 weeks) were, as expected
(17) low and decreased during exendin-4 treatment.
Nuclear cAMP-CREB upregulation stimulates cyclin
A2. Because exendin-4 stimulates both the PI 3-kinase and
cAMP pathways, we assessed speciﬁcally the in vivo
effects of upregulated nuclear cAMP-CREB-CBP signaling
(CBP-S436A knockin mouse) and increased -cell mass
and proliferation (9). CBP-S436A
/ mice exhibited in-
creased -cell Ki67 staining compared with wild-type
littermates. This was paralleled by increased -cell area
without change in -cell size (hyperplasia, not hypertro-
phy) (Fig. 1G–L) (9). In isolated islets, D-type cyclin
protein levels were not different between wild-type and
CBP-S436A
/ mice. In contrast, cyclin A2 levels were
elevated by 2.02  0.20-fold (P  0.05) in CBP-S436A
mutants. p27 was low but detectable in control islets and
below detectable levels in CBP-S436A islets. Skp2, FoxO1,
and Pdx-1 levels were similar in wild-type and in CBP-
S436A littermate islets (Fig. 2B; Table 1). Taken together,
the ﬁndings in CBP-S436A mice suggest that -cell activa-
tion of the cAMP-PKA-CREB-CBP pathway leads to cyclin
A2 expression without changes in PDX-1, FoxO1, and
Skp2.
Exendin-4 stimulates cyclin A2 and PDX-1 transcript
in cultured islets. We next focused on the effects of
exendin-4 on transcript and protein levels of cyclin A2,
cyclin D2 (which among the D-type cyclins is considered
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FIG. 1. Exendin-4 treatment and CBP-S436A
/ mutation result in increased -cell proliferation and islet size. Representative ﬂuorescence
photomicrographs with pseudo-coloring of islet sections of C57Bl/6 littermates treated with either vehicle (PBS) (A) or exendin-4 (B) for 5 days
and of wild-type (G) and CBP-S436A
/ (H) littermates. A, B, G, and H are partitioned as follows: top left, DAPI nuclear stain (blue); top right,
ﬂuorescein isothiocyanate (FITC) immunostain for insulin (green); bottom left, Cy3 immuno-stain for Ki67 (red); and bottom right, a merged
image of the three preceding panels. Compared with controls (A), exendin-4–treated animals (B) exhibit increased islet area (C), -cell
proliferation as assessed by Ki67 in insulin-positive -cells (D), and -cells per islet (E) and unchanged calculated -cell size (F). Similarly,
compared with wild-type controls (G), CBP-S436A
/ mice (H) exhibit increased islet area (I), -cell proliferation as assessed by Ki67 in
insulin-positive -cells (J), and -cells per islet (K) and unchanged calculated -cell size (L). Means  SE in graphs are provided above the
corresponding bars. *Signiﬁcant difference from the corresponding control with P < 0.05. (Please see http://dx.doi.org/10.2337/db07-1541 for a
high-quality digital representation of this ﬁgure.)
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cultured islets, exendin-4 stimulation was associated
with a rapid (within 2 h) approximate twofold upregu-
lation of cyclin A2 transcript (quantitative RT-PCR) and
protein levels. In contrast, PDX-1 transcription and
protein levels increased after 4–6 h of exendin-4 stim-
ulation, whereas cyclin D2 levels remained stable (Fig.
3; Table 2). These results indicate that cyclin A2 tran-
scription responds more rapidly than PDX-1 transcrip-
tion to exendin-4 stimulus.
Exendin-4 stimulates cyclin A2 via cAMP-PKA-CREB
and Skp2 via PI 3-kinase in Min6 cells. In transient
transfections, 20 nmol/l exendin-4 (for 4 h) stimulated
800-bp cyclin A2-LUC reporter activity by 3.7-  0.7-fold
(mean  SE, P  0.05), whereas the CRE mutant of the
reporter (800-bp 	CRE cyclin A2-LUC) showed no stim-
ulation (Fig. 4). The exendin-4 effect was blocked by the
cAMP antagonists H89 and PKI but not by inhibition of the
PI 3-kinase and MEK pathways. Constitutively active cat-
alytic subunit of PKA (PKAcs) signiﬁcantly stimulated
800-bp cyclin A2-LUC reporter activity (4.7-  0.4-fold,
P  0.05) but not that of the corresponding CRE-mutated
reporter. Endogenous cyclin A2 protein levels are stimu-
lated by exendin-4 treatment (see below). CREB overex-
pression stimulated 800-bp cyclin A2-LUC 9.2-  1.1-fold,
whereas dominant-negative A-CREB reduced reporter ac-
tivity to 0.4  0.1 (P  0.05). CREB-CBP (CREB-DIEDML)
stimulated cyclin A2-LUC transcription (data not shown).
Transfection of CREB and CBP together signiﬁcantly
enhanced reporter activity by 7.5-  1.9-fold (P  0.05 vs.
control). Replacement of CBP by the CBP-S436A mutant
increased transcriptional activity by 25.7-  6.6-fold (P 
0.05 vs. control and CBPwt) (Fig. 4).
Based on observations made in CBP-S436A mice, islet
Skp2 levels are not stimulated by the cAMP-CREB-CBP
pathway. Exendin-4–stimulated Skp2 elevation was pre-
vented by pharmacologic PI 3-kinase (Supplemental Fig.
1) but not by cAMP signaling inhibition, respectively. In
summary, in Min6 cells, exendin-4 stimulates cyclin A2
transcription and protein levels by way of cAMP-PKA-
FIG. 2. A: Exendin-4 treatment increases PDX-1, cyclin A2, and Skp-2 and decreases p27 islet protein levels. Islets isolated from C57Bl/6 mice treated
with either vehicle or exendin-4 for 5 days were analyzed for protein levels of cyclin A2 (A), cyclin D1 (B), cyclin D2 (C), PDX-1 (D), p27 (E), and Skp2
(F). B: CBP-S436A
/ islets exhibit increased cyclin A2 and decreased p27 but unchanged PDX-1 and Skp2 protein levels. Islets isolated from wild-type
and CBP-S436A
/ littermates were analyzed for protein levels of cyclin A2 (G), cyclin D1 (H), cyclin D2 (I), PDX-1 (J), p27 (K), and Skp2 (L).
Representative immunoblots are shown together with corresponding immunoblot for actin. Corresponding graphs below the immunoblots depict densito-
metric analysis of antigen band in relation to the corresponding actin band. Data are normalized to the ﬁrst control densitometry, which is depicted as 1.0
in the ﬁrst column of the graph. Numbers indicate absolute value of the corresponding column immediately below them.
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pathway, consistent with previous observations (18).
CREB binds to cyclin A2 but not to D1 or D2 pro-
moter CRE. Using ChIP, we examined whether CREB
occupies endogenous promoter elements of cyclin A2 and
cyclins D1 and D2, which have been reported to contain
CRE elements. In exendin-4–stimulated Min6 cells, we
detected CREB binding to the mouse CRE in insulin 1 and
cyclin A2 promoters but not to CRE of cyclin D1 and D2
promoters (Supplemental Fig. 2). We did not detect any
CREB binding in the absence of exendin-4 treatment of
Min6 cells. This lack of basal binding may reﬂect the low
FIG. 2. Continued
TABLE 1
Relative changes of indicated proteins in total islet extracts in exendin-4–treated (5d) C57Bl/6 mice normalized to vehicle-treated
controls and CBP-S436A normalized to wild-type littermate islet extracts
Protein
Exendin-4 versus
PBS P value
CBP-S436A
/ versus
wild type P value
Cyclin A2 2.69  0.17 0.05 2.02  0.20 0.05
Cyclin B1 0.90  0.20 NS 0.59  0.16 NS
Cyclin B2 0.87  0.31 NS 1.05  0.31 NS
Cyclin D1 1.26  0.06 NS 0.86  0.15 NS
Cyclin D2 1.00  0.09 NS 0.98  0.31 NS
Cyclin D3 1.11  0.12 NS 0.85  0.03 NS
FoxO1 0.79  0.05 0.05 0.98  0.20 NS
p27 Not detected 0.05 Not detected 0.05
Skp2 5.01  0.98 0.05 0.80  0.21 NS
PDX-1 1.93  0.20 0.05 0.85  0.03 NS
Data are means  SE; n 
 4 for each parameter and group. A signiﬁcant difference (P  0.05) from the corresponding control is indicated.
For details, see text.
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endin-4 stimulation stabilizes a larger hetero-protein com-
plex (19) surrounding CREB on the CRE elements of
insulin-1 and cyclin A2 promoters.
Cyclin A2 knockdown inhibits Min6 proliferation and
proliferation stimulation by exendin-4. siRNA trans-
fection achieved 40% knockdown of cyclin A2 protein
(Fig. 5). This resulted in a signiﬁcantly reduced Min6
proliferation rate (1.14  0.02-fold [cyclin A2 siRNA] vs.
1.36  0.05-fold [scrambled siRNA] expansion in 48 h; P 
0.05) (Fig. 5). Cyclin A2 knockdown completely inhibited
exendin-4–induced proliferation stimulation in Min6 cells
(Fig. 5).
Lentiviral-mediated cyclin A2 elevation stimulates
Min6 and primary -cell proliferation. Infection of
Min6 cells with lentivirus expressing cyclin A2 (compared
with control virus) resulted in elevated cyclin A2 levels
and in increased proliferation (fold increase in cell count
within 48 h, 3.9  0.4 vs. 1.5  0.2 in controls, P  0.05) of
Min6 cells (Supplemental Fig. 3).
We next tested the effects of cyclin A2 overexpression in
freshly isolated C57Bl/6 islets. Lentivirus infection rates
were low (5% of insulin-positive -cells) but detectable
by EGFP expression in cultured islets (Supplemental Fig.
4A). Forty-eight hours after exposure to cyclin A2 express-
ing lentivirus, infected -cells showed signiﬁcantly
increased frequency of Ki67- or pH3B-positive nuclei com-
pared with -cells infected with control lentivirus (Fig. 6).
Ki67 is positive throughout most of the cell cycle, whereas
high phospho-histone 3B levels are restricted to the M
phase of the cell cycle. Accordingly, and as expected, Ki67
antigen was detected more frequently than pH3B in cyclin
A2–expressing lentivirus-infected cells. Lentivirus overex-
pression of cyclin A2 in isolated islets resulted in reduced
p27 and unchanged Skp2 protein levels (Supplemental Fig.
7; Supplemental Table 4), consistent with ﬁndings made in
CBP-S436A islets. Taken together, these results indicate
that cyclin A2 overexpression results in increased prolif-
eration activity in primary pancreatic -cells. In contrast
to STZ-treated islets, islets infected with cyclin A2 lentivi-
rus for 48 h did not exhibit any detectable apoptosis
marker cleaved caspase 3 or in the TUNEL assay (20). In
addition, animals treated with exendin-4 and the CBP-
S436A
/ animals did not exhibit cleaved caspase 3 (Sup-
plemental Fig. 4). These data indicate that apoptosis is not
increased in -cells with cyclin A2 overexpression.
Homeodomain transcription factor PDX-1 is required
for cAMP generation and exendin-4 stimulation of
cyclin A2. PDX-1 is required for exendin-4 effects on
-cell proliferation and function (6,8,21). Therefore, we
examined the role of PDX-1 in exendin-4–stimulated cy-
clin A2 expression. siRNA-mediated PDX-1 knockdown for
48 h in Min6 cells had no effect on baseline cyclin A2 levels
(1.02  0.6 compared with no siRNA, NS) but prevented
signiﬁcant increase of cyclin A2 by exendin-4 stimulation
(from 1.02  0.6 to 1.21  0.1 compared with control).
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FIG. 3. A: Exendin-4 stimulates cyclin A2 and PDX-1 transcript in ex
vivo–cultured mouse islets. Cultured isolated C57Bl/6 mouse islets
were exposed to PBS or 20 nmol/l exendin-4 for 0, 2, 4, 6, 8, and 12 h.
Transcript levels of cyclin A2 (A), cyclin D2 (B), and PDX-1 (C) were
measured by quantitative RT-PCR. Transcripts were normalized to
housekeeping gene 36B4 at corresponding time point and are provided
in Table 2 in fold change over baseline (time 0 h) as means  SE of
quadruplicate experiments. *P < 0.05 and statistical signiﬁcant
change. B: Exendin-4 stimulates cyclin A2 and PDX-1 protein in ex
vivo–cultured mouse islets. Cultured isolated C57Bl/6 mouse islets
were exposed to PBS or 20 nmol/l exendin-4 for 0, 2, 4, 6, 8, and 12 h.
Representative immunoblots for cyclin A2, cyclin D2, and PDX-1 are
shown. Densitometric analysis of relative protein levels normalized to
actin at corresponding time points are provided in Table 2 and depicted
as fold change over baseline (0 h) as means  SE of triplicate studies.
*P < 0.05 and statistical signiﬁcant change.
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stimulated 800-bp cyclin A2-LUC activity. Exendin-4–
stimulated cAMP generation was diminished by PDX-1
knockdown. The effect of PDX-1 knockdown on cAMP
generation was seen after 48 h and not after 24 h of PDX-1
knockdown (data not shown), suggesting an indirect effect
of PDX-1 reduction on cAMP generation and cyclin A2
transcription. PKAcs, which acts downstream of cAMP,
rescued 800-bp cyclin A2-LUC activity in Min6 when
siRNA-mediated PDX-1 levels and cAMP generation are
reduced (Supplemental Fig. 5; Supplemental Table 2).
In primary cultured islets, cyclin A2 knockdown did not
inﬂuence exendin-4 stimulation of PDX-1 or of cAMP
generation. In contrast, PDX-1 knockdown prevented ex-
endin-4 effects on cyclin A2 stimulation, which was also
accompanied by reduced exendin-4–induced cAMP gener-
ation (Supplemental Fig. 6; Supplemental Table 3).
On exendin-4 binding to the GLP-1 receptor (GLP-1R),
a trimer of G-coupled proteins associates to the GLP-1R,
of which Gs is instrumental in generating cAMP via
adenylcyclase activation (22). We therefore examined
the effects of siRNA-mediated PDX-1 knockdown on
GLP-1R and Gs expression. PDX-1 knockdown re-
duced both GLP-1R and Gs transcripts (Supplemental
Fig. 8; Supplemental Table 5).
DISCUSSION
The studies herein indicate that in addition to proliferation
stimulation via PI 3-kinase–mediated signaling, exendin-4
stimulates cyclin A2 expression in pancreatic -cells by
way of cAMP-PKA-CREB signaling. The effect of exendin-4
on cyclin A2 transcription stimulation depends on the PI
3-kinase–PKB/Akt-FoxO1-PDX-1 pathway, with PDX-1 be-
ing necessary for adequate exendin-4–stimulated cAMP
generation. Furthermore, in Min6 cells, exendin-4 treat-
ment, via PI 3-kinase–mediated signaling, stimulates Skp2
protein, consistent with previous studies (18). In addition,
our studies suggest that upregulation of cyclin A2 levels
are sufﬁcient to stimulate -cell proliferation.
The two in vivo mouse models presented herein, 1)
exendin-4 stimulated pancreatic -cells and 2) CBP-
S436A
/ knockin mouse models, provide complementary
information on cAMP-dependent and -independent cell
cycle regulation. The former studies provide a model of
incretin trophic effects on -cells, whereas the latter
provide a means to dissect the cAMP-CREB-CBP pathway
from other incretin-induced intracellular signaling path-
ways in the regulation of -cell proliferation. Our in vivo
studies indicate that exendin-4–induced increased -cell
proliferation and mass (Fig. 1) are accompanied by
changes in cell cycle regulatory proteins cyclin A2, Skp2,
and p27 (Figs. 2 and 3). CBP-S436A mutant mice exhibit
hepatic insulin resistance (9), which as stimulus may
contribute to the increased -cell mass. However, as
previously shown, -cells from CBP-S436A
/ mice con-
tinue to proliferate ex vivo in cultured islets, indicating
that the proliferation has a -cell autonomous component
(9). Our studies in Min6 cells indicate that exendin-4–
stimulated cyclin A2 is mediated via cAMP signaling,
whereas Skp2, which has been recently been shown to be
critical in regulating -cell proliferation via p27 degrada-
tion (3,10), is stimulated independently of cAMP signaling
via a PI 3-kinase–mediated pathway. Ex vivo -cell over-
expression of cyclin A2 is associated with stimulated
proliferation activity, as assessed by Ki67 (G1, S, M, and
G2 phases of the cell cycle [23]) and phospho-histone-3B
(M phase [24]) expression without evidence for -cell
apoptosis. Thus, overexpression of cyclin A2 is sufﬁcient
to promote -cell proliferation. These ﬁndings are consis-
tent with the observation that cyclin A2 is unique among
the cyclins in that it regulates progression at both the G1/S
and G2/M checkpoints of mitosis (25) and cyclin A2
overexpression alone in cardiomyocytes stimulates prolif-
eration (26).
A possible additional explanation for increased cyclin
A2 levels in exendin-4–treated mouse islets is increased
Skp2 (Fig. 2; Table 1), which is reported to bind to and
stabilize cyclin A2 levels (27,28). However, CBP-S436A
/
TABLE 2
Exendin-4 stimulates cyclin A2 and PDX-1 in cultured C57Bl6 mouse islets
Treatment
Time (h)
0 2468 1 2
Transcript
Cyclin A2 PBS 1 0.98  0.11 1.09  0.09 1.05  0.04 1.06  0.10 0.99  0.07
Cyclin A2 Exendin-4 1 2.75  0.47* 4.45  0.65* 3.88  0.37* 4.86  0.54* 4.47  0.63*
Cyclin D2 PBS 1 1.09  0.07 1.07  0.05 1.06  0.07 1.05  0.09 0.93  0.10
Cyclin D2 Exendin-4 1 0.99  0.07 1.08  0.09 1.02  0.09 1.18  0.11 1.0  0.15
PDX-1 PBS 1 1.22  0.09 0.99  0.0.07 1.06  0.07 1.05  0.16 0.9  0.16
PDX-1 Exendin-4 1 1.35  0.26 1.06  0.13 2.04  0.67* 6.23  2.88* 7.49  2.97*
Protein
Cyclin A2 PBS 1 0.96  0.38 1.13  0.39 1.13  0.39 1.14  040 0.15  0.40
Cyclin A2 Exendin-4 1 1.56  0.40* 1.82  0.40* 1.68  0.39* 2.01  0.39* 1.69  0.39*
Cyclin D2 PBS 1 1.09  0.07 1.07  0.05 1.06  0.07 1.05  0.09 0.93  0.10
Cyclin D2 Exendin-4 1 0.99  0.07 1.08  0.09 1.02  0.09 1.18  0.11 1.0  0.15
PDX-1 PBS 1 1.15  0.35 1.02  0.35 1.15  0.35 1.14  0.35 0.15  0.36
PDX-1 Exendin-4 1 1.18  0.37 1.55  0.37 1.67  0.36* 1.97  0.36* 2.67  0.35*
Data are means  SE. Relative changes of indicated transcripts and immunoblots of indicated proteins in cultured C57Bl/6 islet extracts
treated with PBS or 20 nmol/l exendin-4 for 0, 2, 4, 6, 8, and 12 h (n 
 4 for each parameter and group). Transcripts were normalized to
housekeeping gene 36B4 transcript at corresponding time points and results are fold change over baseline (0 h). Exendin-4 stimulates an early
(2–4 h) increase in cyclin A2, whereas PDX-1 transcript increases after 6–8 h. Densitometric analysis of relative protein levels normalized
to actin at corresponding time points of three independent experiments are shown as fold change over baseline (0 h). Exendin-4 stimulates
an early (2–4 h) increase in cyclin A2, whereas PDX-1 levels increase after 6–8 h. *Signiﬁcant difference (P  0.05) from the corresponding
control. For details, see text and Fig. 3.
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cyclin A2 without changes in Skp2. In addition, our tran-
sient transfection studies in Min6 cells indicate that intra-
cellular cAMP-PKA signaling directly regulates cyclin A2
transcription. On the basis of these observations, we favor
direct cAMP-CREB-CBP–responsive activation of the cy-
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FIG. 4. Exendin-4 stimulates cyclin A2 transcription via the cAMP-
PKA-CREB-CBP pathway. Min6 cells transiently transfected with
800-bp 5-untranslated region of the murine cyclin A2 gene linked to
a luciferase cDNA (800-bp cyclin A2-LUC) or with the same vector
carrying a mutation in the CRE (800-bp CRE cyclin A2-LUC).
Exendin-4 (20 nmol/l for 4 h) stimulates the intact reporter (A) but not
the reporter with the mutant CRE (B). Co-transfected expression
vector to overexpress active PKAcs stimulates the intact (C) but not
the CRE mutant promoter-reporter (D). Short-term (for 20 min before
exendin-4 treatment) pharmacological inhibition of cAMP (H89 and
PKI), but not other intracellular pathways (U0126 and LY294002)
stimulated by exendin-4, inhibits exendin-4 effects on cyclin A2-LUC
activity (E and F). Co-transfected expression vector to overexpress
CREB stimulates and dominant-negative A-CREB suppresses 800-bp
cyclin A2-LUC activity (G). Co-transfected expression vectors to over-
express CREB and CBP-S4356A mutant stimulate cyclin A2-LUC activ-
ity more potently than CREB with wild-type CBP (CBPwt) (H).
Means  SE in graphs are provided above the corresponding bars.
*Signiﬁcant difference from the corresponding control with P < 0.05.
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FIG. 5. Knockdown of cyclin A2 in Min6 cells reduces proliferation
rate. siRNA-mediated knockdown of cyclin A2 in Min6 cells is ascer-
tained by immunoblot for cyclin A2. A representative immunoblot (A,
top) with densitometric analysis of cyclin A2 relative to actin levels is
shown (A, bottom). Scrambled siRNA does not change cyclin A2 levels
(far right column). Data are normalized to the ﬁrst control densitom-
etry, which is depicted as 1.0 in the ﬁrst column of the graph. Numbers
indicate absolute value of the corresponding column immediately
below them. B: Proliferation rate of Min6 cells is reduced by siRNA
knockdown of cyclin A2, whereas scrambled siRNA does not inﬂuence
proliferation rates. Graph depicts cell number at 48 h normalized to
start (0 h) after no siRNA (left column), cyclin A2-speciﬁc (middle
column), or scrambled siRNA (right column), respectively. C: Prolifer-
ation rate of Min6 cells is increased by exendin-4 (4 h) treatment and
cyclin A2-speciﬁc, but not scrambled siRNA, abolishes the exendin-4
stimulation of cell proliferation. Graph depicts cell number at 48 h
normalized to start (0 h) after no exendin-4, exendin-4 only, exendin-4
plus cyclin A2-speciﬁc siRNA, or scrambled siRNA, respectively.
Means  SE in graphs are provided above the corresponding bars.
*Signiﬁcant difference from the corresponding control with P < 0.05.
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elevated cyclin A2 levels during exendin-4 treatment. It is
important to note that CBP-S436A mutant transcriptional
upregulation is speciﬁc for CREB-CBP interaction and
does not inﬂuence transcription activity of other transcrip-
tion factors such as FoxO1 or hypoxia-inducible factor 1
(9,12).
The islet p27 reduction (Fig. 2), which is required for
cell cycle entry, is common to both mouse models re-
ported here (29). p27 levels are low in the islets of our
relatively young mice (Fig. 2), consistent with observa-
tions that -cell p27 increases with age, which prevents
-cell expansion (17). Reduction of p27 levels may occur
by multiple pathways, which lead to p27 phosphorylation
and phosphorylation-dependent ubiquitination and degra-
dation mediated by Skp2 (rev. in 30). The treatment of
C57Bl/6 mice with exendin-4 and studies in Min6 cells
indicate that Skp2 elevation likely contributes toward p27
reduction, consistent with previous observations (11).
However, in CBP-S436A islets and cyclin A2 overexpres-
sion in islets, changes in Skp2 protein levels are not
required for p27 reduction (Fig. 2; Supplemental Fig. 7).
Formation of cyclin A2–cyclin-dependent kinase (cdk) 1
or A2-cdk 2 complexes lead to p27 phosphorylation and
degradation (31), which likely is achieved with the existing
Skp2 levels in CBP-S436A -cells and cyclin A2 overex-
pression in isolated islets. In summary, p27 levels are most
likely reduced by multiple pathways, and as recently
reported, in -cells Skp2 is required for p27 proteosomal
degradation (11). The CBP-mutant studies indicate that
p27 reduction can be achieved directly or indirectly by
nuclear cAMP-CREB-CBP–responsive transcription. Im-
portantly, exendin-4–treated animals required 5 days to
achieve an increase in islet size similar to that found in
12-week-old CBP-S436A
/ mice. This time difference may
be due in part to elevated Skp2 in exendin-4–treated
animals, and as downstream effects, more rapid -cell
proliferation compared with CBP-S436A islets. Although
FIG. 6. Lentiviral expression of cyclin A2 in mouse islets stimulates -cell proliferation. A–D: Representative pseudo-colored digitally imaged
sections of islets infected for 48 h with control (CMV-; E1f-EGFP) (A and D) or cyclin A2 expressing (CMV-cyclin A2; E1f-EGFP) (B and E)
lentivirus. Sections (Nomarksi image shown in top left subpanels, respectively) are co-immunostained and pseudo-colored for nuclei (DAPI, blue;
top right subpanel), virally expressed EGFP (cyan; middle left subpanel), insulin (Cy5, red; bottom left subpanel), proliferation markers Ki67
(A and B) or phospho-histone-3B (D and E) (yellow; middle right subpanel). The bottom right subpanels depict the corresponding merged image
of the ﬂuorescence channels within the respective panels. White arrows indicate proliferation marker positive and positive lentivirus infection.
Yellow arrows indicate proliferation marker negative, lentivirus postive infection. Quantitaive analysis of proliferation markers Ki67 (C)o r
phospho-histone 3B (F)i n-cells of mouse islets infected for 48 h with control (CMV-; E1f-EGFP) or cyclin A2–expressing (CMV-cyclin A2;
E1f-EGFP) lentiviridae. -Cells infected with cyclin A2–expressing lentivirus (f) show signiﬁcantly more Ki67 (Ki67
/EGFP
) and phospho-
histone 3B (Phospho-H3B
/EGFP
) expression than -cells infected with control virus ()o r-cells not infected at all (Ki67
/EGFP
). Means 
SE in graphs are provided above the corresponding bars. *Signiﬁcant difference from the corresponding control with P < 0.05. (Please see
http://dx.doi.org/10.2337/db07-1541 for a high-quality digital representation of this ﬁgure.)
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stimulation of Skp2 (18), the exact mechanisms underlying
incretin-mediated changes in Skp2 levels in -cells remain
to be elucidated.
-Cell–speciﬁc ablation of PDX-1 markedly reduces
GLP-1–induced -cell proliferation (8), whereas other sa-
lient -cell properties, such as glucokinase activity, mito-
chondrial metabolism, ATP generation (21), and levels of
mRNA transcripts of important proteins such as IRS2,
CREB, and transcription factors Nkx2.2 and Isl1, remain
intact at normal levels (8,21). Consistent with these obser-
vations (5,21), the present ﬁndings conﬁrm that PDX-1
expression is required for cAMP generation in pancreatic
-cells. The association between PDX-1 and exendin-4–
stimulated cAMP formation and downstream cyclin A2
transcription is supported by the following observations:
1) PDX-1 knockdown decreases cAMP generation and
cyclin A2 activation by exendin-4. The effect of PDX-1
knockdown on cAMP generation was seen after 48 h of
PDX-1 knockdown and not after 24 h (data not shown),
which may reﬂect PDX-1 protein half-life and/or an indi-
rect effect of PDX-1. 2) PDX-1 knockdown reduces GLP-1R
and Gs transcript in -cells. 3) PDX-1 knockdown effects
can be rescued by the cAMP downstream effector PKAcs.
And 4) PKA inhibition with H89 or PKI supresses ex-
endin-4 stimulation of cyclin A2 transcription when PDX-1
is not knocked down. In cultured isolated islets, which
have high PDX-1 levels, transcription of cyclin A2 re-
sponds to exendin-4 more rapidly than PDX-1 transcrip-
tion. These results are consistent with indirect (via IRS2
and FoxO1) exendin-4–stimulated PDX-1 expression
(5,32), whereas direct exendin-4-cAMP–mediated cyclin
A2 stimulation occurs more rapidly. Although PDX-1 is
required for cAMP generation, the studies in CBP-
S436A
/ mice argue that augmentation of PDX-1 levels
above baseline is not essential for initiating -cell prolif-
eration (Figs. 1–3).
PDX-1 knockdown is associated with reduced GLP-1R
and Gs transcript in primary islets (Supplemental Fig. 8),
consistent with reports of PDX-1–dependent GLP-1R ex-
pression (8,21). Our studies extend these observations in
that PDX-1 is required for Gs expression. Studies in cell
lines indicate that PDX-1 does not directly regulate
GLP-1R or Gs (33). We therefore speculate that PDX-1
knockdown indirectly reduces GLP-1R and Gs. Further-
more, the ﬁndings herein are consistent with reduced
-cell proliferation in -cell-speciﬁc Gs knockout mice
(22).
In pancreatic -cells, cyclins D1 and D2 and their
interacting partner cdk 4 are essential for postnatal -cell
replication. Mice lacking cyclin D1 and D2 exhibit reduced
-cell mass (3,10). Mice lacking cdk 4 in -cells exhibit
reduced islet mass and diabetes, and mice overexpressing
constitutively active cdk 4 in -cells exhibit increased
-cell proliferation (34,35). The present studies do not
exclude a role for D-type cyclins, for cdk 4 (and 6), or for
nonexendin-4 extracellular growth stimuli in -cell pro-
liferation. Our ﬁndings suggest a differentiated response
of -cells to extracellular growth factors with cyclin A2
being responsive to the cAMP-PKA-CREB-CBP pathway,
whereas the D-type cyclins possibly respond to growth
factor stimuli other than cAMP or PI 3-kinase (36). Previ-
ous reports have suggested that cyclins D1 and D2 respond
to the cAMP pathway in in vitro cell systems (37–39). We
do not ﬁnd any evidence for exendin-4 or CREB-CBP–
mediated elevation in D-type cyclins. Thus, on the basis of
our results, we conclude that in adult -cells, exendin-4
likely does not participate in regulating D-type cyclin
protein levels.
In summary, the current studies indicate that exendin-4
stimulates cyclin A2 transcription and protein levels via
the cAMP-PKA-CREB-CBP pathway. Exendin-4 stimulates
Skp2 levels via the PI 3-kinase pathway. Decreased p27
protein levels accompany these changes. Overexpression
of cyclin A2 by lentivirus infection in primary pancreatic
-cells is sufﬁcient to stimulate -cell proliferation activity.
Furthermore, our studies provide additional evidence for
the central role of homeodomain transcription factor
PDX-1 in -cell proliferation, with PDX-1 being required
for cAMP generation.
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